Bovimox 5 mg/ml Pour-on Solution for Cattle

Care should be taken to avoid the following practices because they increase the risk of
development of resistance and could ultimately result in ineffective therapy:
- Too frequent and repeated use of anthelmintics from the same class, over an extended
period of time.
- Underdosing, which may be due to underestimation of bodyweight, misadministration of
the product, or lack of calibration of the dosing device (if any).
Suspected clinical cases of resistance to anthelmintics should be further investigated
using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the
test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging
to another pharmacological class and having a different mode of action should be used.
Selection of resistant genes leading to the development of resistance can ultimately result
in ineffective anthelmintic therapy.
Partial cross-resistance between ivermectin and moxidectin has been reported in
nematode parasites. Cases of resistance to moxidectin have been reported in
gastrointestinal nematode parasites of cattle. Therefore, use of this product should be

Revised: November 2025
AN: 02301/2025
based on local (regional, farm) epidemiological information about susceptibility of
parasites, local history of treatments and recommendations on how to limit further
selection for resistance to anthelmintics.

Special precautions for use in animals
For topical application only.
Avermectins may not be well tolerated in all non-target species. Cases of intolerance with
fatal outcome are reported in dogs, especially Collies, Old English Sheepdogs and related
breeds or crosses, and also in turtles/tortoises.
Care should be taken to avoid ingestion of spilled product or access to containers by
these other species.
To avoid secondary reactions due to the death of Hypoderma larvae in the oesophagus or
the spine, it is recommended to administer the product at the end of the period of fly
activity and before the larvae reach their resting sites: consult the veterinarian to know the
correct treatment period.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals
This product can cause skin and eye irritation. Avoid direct contact with skin and eyes.
Do not smoke, eat or drink when handling this product.
Wear impermeable rubber gloves and protective clothes during use.
Wash hands or any exposed area after use.
In the event of eye contact, flush the eye with copious amounts of clean water and seek
medical advice
Other precautions regarding impact on the environment
Moxidectin fulfils the criteria for a (very) persistent, bioaccumulative and toxic (PBT)
substance; therefore, exposure of the environment to moxidectin must be limited to the
extent possible. Treatments should be administered only when necessary and should be
based on faecal egg counts or evaluation of the risk of infestation at the animal and/or
herd level.
Like other macrocyclic lactones, moxidectin has the potential to adversely affect non-
target organisms:
• Faeces containing moxidectin excreted onto pasture by treated animals may temporarily
reduce the abundance of dung feeding organisms. Following treatment of cattle with the
product, levels of moxidectin that are potentially toxic to dung fly species may be
excreted over a period more than 2 weeks and may decrease dung fly abundance
during that period. It has been established in laboratory tests that moxidectin may
temporarily affect dung beetle reproduction; however, field studies indicate no-long term
effects. Nevertheless, in case of repeated treatments with moxidectin (as with products
of the same anthelmintic class) it is advisable not to treat animals every time on the
same pasture to allow dung fauna populations to recover.
• Moxidectin is inherently toxic to aquatic organisms including fish. The product should be
used only according to the label instructions. Based on the excretion profile of

Revised: November 2025
AN: 02301/2025
moxidectin when administered as the pour-on formulation, treated animals should not
have access to watercourses during the first week after treatment.